Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 327-332 |
| Journal | ONCOLOGIST |
| Volume | 21 |
| Issue number | 3 |
| Publication status | Published - 2016 |
Fingerprint
Cite this
}
Impact of a patient blood management program and an outpatient anemia management protocol on red cell transfusions in oncology inpatients and outpatients. / Gross, I.; Trentino, K.M.; Andreescu, A.; Pierson, R.; Maietta, R.A.; Farmer, Shannon.
In: ONCOLOGIST, Vol. 21, No. 3, 2016, p. 327-332.Research output: Contribution to journal › Article
TY - JOUR
T1 - Impact of a patient blood management program and an outpatient anemia management protocol on red cell transfusions in oncology inpatients and outpatients
AU - Gross, I.
AU - Trentino, K.M.
AU - Andreescu, A.
AU - Pierson, R.
AU - Maietta, R.A.
AU - Farmer, Shannon
PY - 2016
Y1 - 2016
N2 - © AlphaMed Press 2016. Background. Patient blood management (PBM) programs are associated with reduced transfusion usage, reduced hospital costs, and improved patient outcomes.The application of PBM principles in patients with malignant disease might achieve similar results. However, this population presents unique challenges. The aim of the present study was to investigate the impact of a PBM program on blood usage and patient outcomes in cancer patients, particularly in the setting of restricted use of erythropoiesis-stimulating agents (ESAs). Materials and Methods. A retrospective observational study was performed of patients admitted with a primary diagnosis of malignancy treated at Eastern Maine Medical Center as inpatients or outpatients, or both, from January 2008 through July 2013. Results. The proportion of inpatients and outpatients receiving ESAs decreased from 2.9% in 2008 to 1.1% in 2013 (p
AB - © AlphaMed Press 2016. Background. Patient blood management (PBM) programs are associated with reduced transfusion usage, reduced hospital costs, and improved patient outcomes.The application of PBM principles in patients with malignant disease might achieve similar results. However, this population presents unique challenges. The aim of the present study was to investigate the impact of a PBM program on blood usage and patient outcomes in cancer patients, particularly in the setting of restricted use of erythropoiesis-stimulating agents (ESAs). Materials and Methods. A retrospective observational study was performed of patients admitted with a primary diagnosis of malignancy treated at Eastern Maine Medical Center as inpatients or outpatients, or both, from January 2008 through July 2013. Results. The proportion of inpatients and outpatients receiving ESAs decreased from 2.9% in 2008 to 1.1% in 2013 (p
M3 - Article
VL - 21
SP - 327
EP - 332
JO - ONCOLOGIST
JF - ONCOLOGIST
SN - 1083-7159
IS - 3
ER -